CDT Equity Inc.

AI-generated fair value estimate for this company.

Method: Net-asset-plus-option-value approach: about $0.75M cash less $1.18M debt gives roughly -$0.43M net debt, so a modest risk-adjusted option value of about $1.6M was added for the Phase II AZD1656 and Phase I AZD5658 pipeline plus the 22% Sarborg Limited quantum-computing-for-drug-discovery stake, since the $103M GAAP book equity figure reflects non-cash fair-value marks not considered realizable; the sum was divided by 1.12M shares outstanding.

Reasoning: With no revenue, negative net cash, and going-concern risk, a DCF is not meaningful; the standard way to value a cash-strapped clinical-stage biopharma with no near-term pivotal catalysts is net realizable assets plus a heavily discounted option value on its pipeline and investee stake, which lands close to where the market (around $0.99/share) already prices it.